Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 11;15(9):e0210024.
doi: 10.1128/mbio.02100-24. Epub 2024 Aug 22.

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Affiliations
Review

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Ana Maria Ortega-Prieto et al. mBio. .

Abstract

The coronavirus disease 2019 (COVID-19) pandemic remains an international health problem caused by the recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of May 2024, SARS-CoV-2 has caused more than 775 million cases and over 7 million deaths globally. Despite current vaccination programs, infections are still rapidly increasing, mainly due to the appearance and spread of new variants, variations in immunization rates, and limitations of current vaccines in preventing transmission. This underscores the need for pan-variant antivirals and treatments. The interferon (IFN) system is a critical element of the innate immune response and serves as a frontline defense against viruses. It induces a generalized antiviral state by transiently upregulating hundreds of IFN-stimulated genes (ISGs). To gain a deeper comprehension of the innate immune response to SARS-CoV-2, its connection to COVID-19 pathogenesis, and the potential therapeutic implications, this review provides a detailed overview of fundamental aspects of the diverse ISGs identified for their antiviral properties against SARS-CoV-2. It emphasizes the importance of these proteins in controlling viral replication and spread. Furthermore, we explore methodological approaches for the identification of ISGs and conduct a comparative analysis with other viruses. Deciphering the roles of ISGs and their interactions with viral pathogens can help identify novel targets for antiviral therapies and enhance our preparedness to confront current and future viral threats.

Keywords: COVID-19; ISG; SARS-CoV-2; innate immunity; interferon.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Comparative analysis of methodological approaches for identifying ISGs with antiviral activity, highlighting the key strengths and limitations of each method and the ISGs identified with antiviral activity against SARS-CoV-2.
Fig 2
Fig 2
Schematic representation of the IFN response, the SARS-CoV-2 viral life cycle, and different ISGs identified with antiviral activity. (a) Schematic representation of the IFN response where the recognition of pathogen-associated molecular patterns (PAMPs) by specific pattern recognition receptors (PRRs) encoded by the host leads to the production and secretion of interferon, subsequently inducing an antiviral state involving the transcriptional upregulation of hundreds of IFN-stimulated genes (ISGs) with potential antiviral properties. (a) Schematic representation of the SARS-CoV-2 viral life cycle and various ISGs identified with antiviral activity. The ISGs identified are indicated in green boxes, and the viral proteins antagonizing their antiviral activity are indicated in light blue ovals.

Similar articles

Cited by

References

    1. Cui J, Li F, Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192. doi:10.1038/s41579-018-0118-9 - DOI - PMC - PubMed
    1. Graham RL, Donaldson EF, Baric RS. 2013. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836–848. doi:10.1038/nrmicro3143 - DOI - PMC - PubMed
    1. Amanat F, Krammer F. 2020. SARS-CoV-2 vaccines: status report. Immunity 52:583–589. doi:10.1016/j.immuni.2020.03.007 - DOI - PMC - PubMed
    1. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21:1508–1513. doi:10.1038/nm.3985 - DOI - PMC - PubMed
    1. de Wit E, van Doremalen N, Falzarano D, Munster VJ. 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. doi:10.1038/nrmicro.2016.81 - DOI - PMC - PubMed